Solitary Fibrous Tumourbase

Solitary Fibrous Tumour (SFT) is a mesenchymal neoplasm that primarily originates in the pleural region and mostly occurs in the thoracic cavity of humans. In 2016, the World Health Organization (WHO) classified solitary fibrous tumours (SFT) and hemangiopericytoma (HPC) into one category. Although they were classified into one entity yet, they are behaviourally distinct. It affects adults between the age of 20 and 70 years. Results obtained from clinical sequencing of the whole-exome and transcriptome revealed that NAB2-STAT6 fusion causes SFT. The fusion between a transcriptional repressor (NAB2) and transcriptional activator (STAT6) initiates the transformation of a transcription repressor to the transcriptional activator and enhances EGFR1-induced promoter activity. Major diagnostic options available for SFT comprises imaging techniques (CT, X-rays, MRI, PET), biopsy (Core needle and surgical), immunohistochemistry and RT-PCR analysis. Treatment approaches include Surgery as the first-line of treatment and chemotherapy and radiotherapy. Both of them are invasive procedures for the patients. A solitary fibrous tumour (SFT) is a rare tumour of mesenchymal origin that account for less than 2% of all soft tissue masses.